首页> 外文OA文献 >P359 A novel phase 1 trial design to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TOP1288, a narrow spectrum kinase inhibitor, delivered topically to the colon via oral administration

【2h】

P359 A novel phase 1 trial design to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TOP1288, a narrow spectrum kinase inhibitor, delivered topically to the colon via oral administration

机译：P359一种新型的第1阶段试验设计，以评估TOP1288的安全性，耐受性，药代动力学和药效学，窄谱激酶抑制剂，通过口服给药局部递送至结肠

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
A Rowley; M Taylor; A Duggal; M Foster; S Sirohi; Y Solanke; C Walshe; M Fyfe; S Webber; S Travis;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Randomized Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Topical Daprodustat in Healthy Volunteers and in Patients With Diabetic Foot Ulcers [J] . Olson Eric, Mahar Kelly M., Morgan Lisa, Clinical pharmacology in drug development . 2019,第6期

机译：随机阶段I试验，以评估局部Daprodustat在健康志愿者和糖尿病足溃疡患者中的局部Daprodustat的安全性，耐受性，药代动力学和药效学
2. Randomized Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Topical Daprodustat in Healthy Volunteers and in Patients With Diabetic Foot Ulcers [J] . Olson Eric, Mahar Kelly M., Morgan Lisa, Clinical pharmacology in drug development . 2019,第S1期

机译：随机阶段I试验，以评估局部Daprodustat在健康志愿者和糖尿病足溃疡患者中的局部Daprodustat的安全性，耐受性，药代动力学和药效学
3. Phase i safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors [J] . SoriaJ.-C., CortesJ., MassardC., Annals of oncology: official journal of the European Society for Medical Oncology . 2012,第2期

机译：口服pan-HER受体酪氨酸激酶抑制剂BMS-599626（AC480）在患有晚期实体瘤的患者中的第一阶段安全性，药代动力学和药效学试验
4. Evaluation of the pharmacokinetic-pharmacodynamic relationship, metabolism and plasma protein binding of the novel antitumor agent, 2-methoxyestradiol (2ME2), following oral administration in patients with solid tumors. [D] . Lakhani, Nehal Jagdish. 2005

机译：实体瘤患者口服后评估新型抗肿瘤药2-甲氧基雌二醇（2ME2）的药代动力学与药效关系，代谢和血浆蛋白结合。
5. Phase I Clinical Study of ZYAN1 A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety Tolerability and Pharmacokinetics Following Oral Administration in Healthy Volunteers [O] . Kevinkumar A. Kansagra, Deven Parmar, Rajendra H. Jani, -1

机译：新型脯氨酰羟化酶（PHD）抑制剂ZYAN1的一期临床研究旨在评估健康志愿者口服后的安全性耐受性和药代动力学
6. Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers [O] . Kevinkumar A. Kansagra, Deven Parmar, Rajendra H. Jani, 2017

机译：Zyan1，一种新型脯氨酰 - 羟化酶（PHD）抑制剂的临床研究，以评估在健康志愿者口服施用后的安全性，耐受性和药代动力学

P359 A novel phase 1 trial design to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TOP1288, a narrow spectrum kinase inhibitor, delivered topically to the colon via oral administration

著录项

相似文献

相关主题

期刊订阅